C. Manegold

3.6k total citations · 1 hit paper
82 papers, 2.4k citations indexed

About

C. Manegold is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, C. Manegold has authored 82 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Pulmonary and Respiratory Medicine, 37 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in C. Manegold's work include Lung Cancer Treatments and Mutations (40 papers), Lung Cancer Research Studies (20 papers) and Lung Cancer Diagnosis and Treatment (18 papers). C. Manegold is often cited by papers focused on Lung Cancer Treatments and Mutations (40 papers), Lung Cancer Research Studies (20 papers) and Lung Cancer Diagnosis and Treatment (18 papers). C. Manegold collaborates with scholars based in Germany, United States and Netherlands. C. Manegold's co-authors include Joachim von Pawel, Martin Reck, Petr Zatloukal, Rodryg Ramlau, Vera Hirsh, J. Mezger, Norman C. Moore, Venice Archer, N. B. Leighl and V. Gorbounova and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Gut.

In The Last Decade

C. Manegold

80 papers receiving 2.3k citations

Hit Papers

Overall survival with cisplatin–gemcitabine and bevacizum... 2010 2026 2015 2020 2010 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
    2010 498 citations Martin Reck, Joachim von Pawel et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Manegold Germany 21 1.5k 1.1k 407 240 236 82 2.4k
Domenico Galetta Italy 28 1.5k 1.0× 1.3k 1.2× 374 0.9× 171 0.7× 284 1.2× 175 2.8k
Laurent Greillier France 28 1.8k 1.2× 1.6k 1.4× 530 1.3× 187 0.8× 151 0.6× 206 3.0k
Gavin Wright Australia 27 2.1k 1.4× 1.3k 1.1× 463 1.1× 402 1.7× 380 1.6× 128 3.0k
Bryan J. Schneider United States 26 1.2k 0.8× 1.6k 1.4× 613 1.5× 180 0.8× 251 1.1× 75 2.8k
Matias Riihimäki Sweden 12 821 0.5× 1.4k 1.2× 348 0.9× 179 0.7× 460 1.9× 12 2.2k
Paolo Bidoli Italy 27 1.9k 1.2× 2.0k 1.7× 531 1.3× 100 0.4× 365 1.5× 127 3.1k
Tomonori Hirashima Japan 31 1.9k 1.2× 1.7k 1.4× 543 1.3× 147 0.6× 246 1.0× 146 2.7k
Robin Rudd United Kingdom 22 1.6k 1.0× 930 0.8× 428 1.1× 171 0.7× 129 0.5× 50 2.4k
Meghan J. Mooradian United States 19 1.2k 0.8× 1.8k 1.6× 472 1.2× 191 0.8× 156 0.7× 68 2.6k
Michele Aieta Italy 24 997 0.7× 1.2k 1.0× 638 1.6× 166 0.7× 315 1.3× 116 2.3k

Countries citing papers authored by C. Manegold

Since Specialization
Citations

This map shows the geographic impact of C. Manegold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Manegold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Manegold more than expected).

Fields of papers citing papers by C. Manegold

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Manegold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Manegold. The network helps show where C. Manegold may publish in the future.

Co-authorship network of co-authors of C. Manegold

This figure shows the co-authorship network connecting the top 25 collaborators of C. Manegold. A scholar is included among the top collaborators of C. Manegold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Manegold. C. Manegold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lesaffre, Emmanuel, Martin J. Edelman, Nasser H. Hanna, et al.. (2017). Statistical controversies in clinical research: futility analyses in oncology–lessons on potential pitfalls from a randomized controlled trial. Annals of Oncology. 28(7). 1419–1426. 10 indexed citations
2.
Gridelli, Cesare, Tudor–Eliade Ciuleanu, M. Dómine Gómez, et al.. (2017). Randomized double blind phase IIb trial in advanced NSCLC patients who did not progress after first line platinum based chemotherapy: Vx-001, a therapeutic cancer vaccine, vs placebo as maintenance therapy. Annals of Oncology. 28. v638–v638. 3 indexed citations
3.
Su, Chunxia, Lihong Fan, Li-Mou Zheng, et al.. (2013). ROS1 fusions in Chinese patients with non-small-cell lung cancer. Annals of Oncology. 24(7). 1822–1827. 69 indexed citations
4.
Manegold, C., Nico van Zandwijk, A. Szczęsna, et al.. (2011). A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Annals of Oncology. 23(1). 72–77. 117 indexed citations
5.
Schmid‐Bindert, Gerald, Thomas Henzler, Mathias Meyer, et al.. (2011). Functional imaging of lung cancer using dual energy CT: how does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT?. European Radiology. 22(1). 93–103. 104 indexed citations
6.
Mudduluru, Giridhar, et al.. (2010). Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules. British Journal of Cancer. 103(6). 802–811. 20 indexed citations
7.
Reck, Martin, Joachim von Pawel, Petr Zatloukal, et al.. (2010). Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Annals of Oncology. 21(9). 1804–1809. 498 indexed citations breakdown →
8.
9.
Scagliotti, Giorgio V., Aleksandra Szczęsna, Rodryg Ramlau, et al.. (2006). Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer. British Journal of Cancer. 94(10). 1375–1382. 25 indexed citations
10.
Surmont, Veerle, R.J. van Klaveren, C. Manegold, et al.. (2006). Lessons to learn from EORTC study 08981: A feasibility study of induction chemoradiotherapy followed by surgical resection for stage IIIB non-small cell lung cancer. Lung Cancer. 55(1). 95–99. 9 indexed citations
11.
12.
Gridelli, Cesare, C. Manegold, P Mali, et al.. (2004). Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. European Journal of Cancer. 40(16). 2424–2431. 36 indexed citations
13.
Eberhardt, Wilfried, Kathy S. Albain, Harvey I. Pass, et al.. (2003). Induction treatment before surgery for non-small cell lung cancer. Lung Cancer. 42(2). 9–14. 44 indexed citations
14.
Manegold, C.. (2003). Docetaxel (Taxotere<sup>®</sup>) in der First-line-Therapie des fortgeschrittenen nicht-kleinzelligen Bronchialkarzinoms (NSCLC). Oncology Research and Treatment. 26(7). 26–32. 5 indexed citations
15.
Manegold, C.. (2003). Pemetrexed (alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma. Seminars in Oncology. 30(4 Suppl 10). 32–36. 19 indexed citations
16.
Manegold, C.. (2001). Chemotherapy for advanced non-small cell lung cancer. Seminars in Oncology. 28(2 Suppl 7). 1–6. 7 indexed citations
17.
Manegold, C., U. Gatzemeier, Joachim von Pawel, et al.. (2000). Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™ and cisplatin: A multicenter phase II trial. Annals of Oncology. 11(4). 435–440. 127 indexed citations
18.
Zimmermann, Annamaria H., et al.. (1995). Gastric Cancer and Lymphoma. Gut. 37(Suppl 1). A38–A40. 2 indexed citations
19.
Steinke, B., H.-M. Reinold, Manfred Heim, et al.. (1992). Cyclic alternating chemotherapy of high-grade malignant non-Hodgkin lymphomas with VIM-Bleo and CHOP. European Journal of Cancer. 28(1). 100–104. 5 indexed citations
20.
Manegold, C., et al.. (1992). Oral ifosfamide-mesna: A clinical investigation in advanced non-small-cell lung cancer. Annals of Oncology. 3(9). 723–726. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Domenico Galetta Breakdown of academic impact, for papers by Laurent Greillier Breakdown of academic impact, for papers by Gavin Wright Breakdown of academic impact, for papers by Bryan J. Schneider Breakdown of academic impact, for papers by Matias Riihimäki Breakdown of academic impact, for papers by Paolo Bidoli Breakdown of academic impact, for papers by Tomonori Hirashima Breakdown of academic impact, for papers by Robin Rudd Breakdown of academic impact, for papers by Meghan J. Mooradian Breakdown of academic impact, for papers by Michele Aieta
Rankless by CCL
2026